<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187093</url>
  </required_header>
  <id_info>
    <org_study_id>11031215</org_study_id>
    <nct_id>NCT03187093</nct_id>
  </id_info>
  <brief_title>Cognitive Dysfunction in MDD Patients</brief_title>
  <official_title>Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oleg Levada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Institution, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major Depressive Disorder (MDD) is one of the most prevalent mental diagnosis within the
      worldwide population. Although there is evidence about relationship between MDD and cognitive
      dysfunction, still the correlations between biomarkers and the severity of the disorder or
      the level of cognitive dysfunction need further research. Therefore, the aim of the study is
      to determine such relationships in Ukrainian population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline to week 8 in DSST</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in MADRS</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in PDQ-5-D</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in RAVLT</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in TMT-B</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in plasma levels of IGF-1</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in plasma levels of IL-1</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in plasma levels of IL-6</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in plasma levels of TNF-α</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in plasma levels of cortisol</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to week 8 in plasma levels of ACTH</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Vortioxetine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>10-20 mg once daily for 8 weeks</description>
    <arm_group_label>Vortioxetine</arm_group_label>
    <other_name>Brintellix</other_name>
    <other_name>Trintellix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10-20 mg once daily for 8 weeks</description>
    <arm_group_label>Escitalopram</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient 20 to 60 years of age

          -  Meets DSM-5 criteria for MDD

          -  The participant has MARDS total score ≥10

        Exclusion Criteria:

          -  Any other psychiatric diagnosis that is considered the primary diagnosis

          -  Substance dependence/abuse in the past 6 months

          -  Significant neurological disorders

          -  Psychosis in the current episode

          -  High risk for hypomanic switch (i.e., history of antidepressant-induced hypomania)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Oleg A. Levada, MD, ScD</last_name>
    <phone>+380672623972</phone>
    <email>olevada@zmapo.edu.ua</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandra Troyan</last_name>
    <phone>+380673287519</phone>
    <email>troian@zmapo.edu.ua</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>State Institution &quot;Zaporizhzhia Medical Academy of Postgraduate Education Ministry of Health of Ukraine&quot;</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Troyan, MD</last_name>
      <phone>+380673287519</phone>
      <email>troian@zmapo.edu.ua</email>
    </contact>
  </location>
  <location_countries>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>State Institution, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine</investigator_affiliation>
    <investigator_full_name>Oleg Levada</investigator_full_name>
    <investigator_title>MD, ScD (psychiatry), PhD (neurology), Psychiatry course chief</investigator_title>
  </responsible_party>
  <keyword>MDD</keyword>
  <keyword>Vortioxetine</keyword>
  <keyword>IGF-1</keyword>
  <keyword>Cognitive dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Vortioxetine</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

